Clinical Trials What are they?
|
|
- Kristina Atkinson
- 5 years ago
- Views:
Transcription
1 Newer Agents And Combinations in Myelodysplastic Syndromes Ruben A. Mesa, MD Mayo Clinic Arizona David P. Steensma, MD Dana-Farber Cancer Institute What are they? Biomedical or health-related related research studies in human beings that follow a predeterminded protocol (document detailing uniform treatment) Two major types Interventional-when patients are assigned a treatment Observational-when patients are observed Why participate? Patients play an active role in their own health care, they become engaged Patients can gain access to new treatments that may not be otherwise available, before formal governmental (FDA) approval Patients can help others by contributing to medical research and helping establish new and better treatments for future patients 1
2 Who can or should participate? Patients with a disease where treatment is not curative Clinical trials have inclusion and exclusion criteria to Protect the safety of the patient from the new treatment being tested Help produce reliable results which will make sure the trial really determines if the new treatment is effective Inclusion/exclusion criteria include age, type and stage of disease, prior treatment history, organ function (heart, lung, kidneys) to make sure the treatment is safe Informed consent Process of learning the facts of the clinical trial before deciding whether or not to participate Details are explained by the treating physician, nurse and other professionals Document must be signed which includes purpose of the clinical trial and treatment, duration, required procedures, risks and potential benefits Benefits Patients play an active role in their health care Patients can gain access to new treatments before they are approved by the government (FDA) and widely available Patients can help others by contributing to medical research to identify new and better treatment 2
3 Risks There may be side effects, some lifethreatening Treatment under study in the clinical trial may not be effective Treatment on the clinical trial may require more time and tests than required by what we call standard (routine or nonprotocol or nonclinical trial) treatment Phases Phase I-designed to determine the best and safest dose and identify side effects Phase II-designed to determine the effectiveness of the new treatment Phase III-designed to compare the effectiveness of the new treatment to the commonly used treatment Phase IV-postmarketing (after FDA approval) trial to further refine the risks and benefits and identify new side effects once the new treatment is widely used Sponsors and funding (financial support) University medical centers, cancer centers Foundations Pharmaceutical industry Federal agencies such as the National Institutes of Health, Cooperative oncology groups 3
4 Outline Combination approaches Azacitidine + MS275 Azacitidine + SAHA (vorinostat) Newer agents Oral azacitidine Oral TLK199 (ezatiostat) IV and oral clofarabine IV ON01910.Na Alemtuzumab (IV) Combination Approaches Azacitidine Combination Studies Combination Patient Population Response Azacitidine + lenalidomide Azacitidine + etanercept Azacitidine + vorinostat Azacitidine + MGCD0103 Azacitidine + gemtuzumab Azacitidine + romiplostim High-risk MDS (n = 18) MDS (low to high risk) (n = 18) MDS, elderly AML (n = 18) MDS, R/R AML (n = 52) AML/high-risk MDS (n = 15) Low/int-1 MDS azacitidine or decitabine Overall RR: 67% CR: 44% CR: 72% (13/18) CR: 50% (9/18) CR/CRi: 35%; PR: n = 1 (18/52) CR + CRp: 72% (11/15) Platelet response CR = complete response, R/R = relapsed/refratory, RR = response rate 4
5 ECOG E1905 study schema Eligible patients (no prior azacitidine): MDS (higher risk; if IPSS low/int-1 risk, then platelets <50 x 10 9 /L or ANC<500) CMML with WBC <12 x 10 9 /L AML with multilineage dysplasia and WBC 30 x 10 9 /L for 4 weeks Azacitidine SC 50 mg/m 2 x 10 days every 28 days Randomize 1:1 Primary Endpoint: IWG 2000 responses with hematological normalization (CR+PR+trilineage HI) Azacitidine SC 50 mg/m 2 x 10 days every 28 days, plus Entinostat (MS-275) 4 mg/m2 PO days 3 and 10 each cycle E1905 enrolled patients Number enrolled Median age Diagnosis: 150 (137 eligible, 136 evaluable) 72 years MDS n=88 CMML n=5 AML n=43 IPSS Int-2/High 72% Poor risk cytogenetics 31% Prebet T et al, ASH 2010, Abstract #601 Response / AE E1905 study results Comparator -- CALGB 9221 study: CR + PR + trilineage HI rate = 15% Arm A (azacitidine monotherapy) Arm B (combination therapy) Complete response (CR) 12% 7% Partial response (PR) 9% 7% Trilineage hematological improvement (thi) Qualifying Response (CR+PR+tHI) Other hematological improvement 10% 10% 31% 24% (p=ns) 12% 19% Any response 43% 44% Grade IV thrombocytopenia 44% 63% (p=0.07) Grade III/IV fatigue 13% 23% (p=0.13) Prebet T et al, ASH 2010, Abstract #601 5
6 ASH 2010 Abstract #604 Phase II Study of 5-azacytidine and vorinostat in patients with newly diagnosed MDS or AML not eligible for clinical trials because poor performance or presence of other comorbidities Guillermo Garcia-Manero, Elihu Estey, Elias Jabbour, Tapan Kadia, Zeev Estrov, Jorge Cortes, Ross Levine, Hui Yang, Pat Boone and Hagop Kantarjian Department of Leukemia, University of Texas MD Anderson Cancer Center; Fred Hutchinson Cancer Research Center, and Memorial Sloan Kettering Cancer Center AZA + SAHA: Patient eligibility Untreated MDS ( Int-1) or AML And any of the following: Total bilirubin 2 mg/dl Creatinine 2 mg/dl ECOG performance status > 2 Excluded from any other clinical trial Dose and schedule: AZA 75 mg/m2 IV QD days 1 to 5 SAHA 200 mg PO TID days 1 to 5 Cycles repeated every 28 days 6
7 AZA+ SAHA: Patient Characteristics Characteristic Total N=27 Median age (range) Median % BM blasts (range) Diagnosis (%) AML MDS Median (range) Total bilirubin Creatinine 69 (44-83) 20 (2-62) 9 (33) 18 (66) 1.1 ( ) 1.2 ( ) WBC 14 ( ) Cytogenetics (%) Diploid Unfavorable N eligible for creatinine N eligible for Total Bili N eligible for malignancy * N eligible other* 7 (25) 20 (75) 4 (14) 3 (11) 10 (37) 10 (37) *Metastatic sarcoma, met ovarian, met breast ca (3), prostate ca, CLL(2), NHL (2), GBM, liver cirrhosis (2), CHF (2), COPD, bone dx Toxicity (Any Grade) AZA + SAHA Non-Hematological Toxicity (N=24, courses= 48) N o Pts Course 1 Course 2 Diarrhea 7 3 Nausea/Vomiting 6 4 Constipation 4 Fatigue 3 2 Hepatic 3 Rash 1 AZA+ SAHA: Complete Responses N CR OR % Median Courses to Response (range) Evaluated: (1-9) Stopping rule for CR: 4 CR in 30 achieved by patient # 8 7
8 Novel Agents 23 Evaluation of Oral Azacitidine Using Extended Treatment Schedules: A Phase I Study (Abstract 603) G. Garcia-Manero, S.D. Gore, C.R. Cogle, E.J. Jabbour, M.R. Ward, K.J. MacBeth, E. Laille, H. Giordano, H.M. Kantarjian, and B.S. Skikne Department of Leukemia, M.D. Anderson Cancer Center, Houston, TX, USA; The Sidney Kimmel Cancer Center, Johns Hopkins University, Baltimore, MD, USA; University of Florida, Gainesville, FL, USA; Celgene Corporation, Summit, NJ, USA Extended dosing oral azacitidine in MDS: phase I Design and patients Eligibility: Age 18 with MDS, CMML, or AML Hb 9 g/dl or platelets <50 x 10 9 /L No prior azanucleoside therapy Starting dose: 300 mg QD or 200 mg BID for 14/28 or 21/28 days Cohorts of 6, DLT assessment after Cycle 1 Enrolled patients thus far: 25 (14 M : 11 F), median age 68 (range 44-87) MDS (n=13) AML (de novo, n=7; post-mds, n=3) CMM: (n=2) Garcia-Manero et al, ASH 2010 Abstract #603 8
9 Extended dosing oral azacitidine in MDS: phase I Results Adverse events: 2 DLTs (grade 3 N/V) in patients on 14 days QD dosing No DLTs yet on 21 days QD, 14 day BID, 21 day BID No dose escalation/mtd definition yet Rate of febrile neutropenia highest with 21-day QD cohort PK: mean first/last day drug exposure 26-58% of historically expected SC drug exposure (AUC) Updated response data at meeting on 15 MDS patients: CR in 2/15 (IWG 2006 criteria) Any HI in 6/14 RBC transfusion freedom in 3/5 Garcia-Manero et al, ASH 2010 Abstract #603 Townsend DM et al Oncogene 2003; Steensma D Hem/Onc Clin N America 2010 Phase I/II Study of Intravenous Liposomal TLK199 in MDS Liposome n=54 Responses: Trilineage responses in 4/16 pts (25%) with pancytopenia HI-E in 9/38 (24%) anemic pts HI-N in 11/26 (42%) neutropenic pts HI-P in 12/24 (50%) thrombocytopenic pts Adverse events: Most mild & attributable to liposomal preparation (e.g. back pain, chills, nausea, bone pain, and diarrhea) Raza A et al J Hematol Oncol 2:20,
10 Phase I Study of Oral TLK199 (Ezatiostat) in MDS n=45, IPSS Low to INT-2, median age 71 Starting dose 200 mg Up to 6,000 mg/day ezatiostat divided into 2 doses days 1-7 out of 21-day cycle was tolerated, without a DLT 17/45 (38%) had His by IWG 2000, most (11) at higher end of dose range ( 4 g/day) 6/29 HI-E, 4/19 HI-N, 7/21 HI-P Adverse events (all grade ½): nausea (65%) diarrhea (43%) vomiting (31%) constipation (13%) abdominal pain (9%) Raza A et al Blood 113:6533, 2009 Ongoing Phase II TLK199 Study n=86, 36 participating centers Eligible: De novo IPSS Low/Int-1 MDS Endpoint: HI-E (primary) Schedule 1: Ezatiostat 4500 mg/day in 2 divided doses PO for 2 weeks on, 1 week off Schedule 2: Ezatiostat 4500 mg/day in 2 divided doses PO for 3 weeks on, 1 week off Clinicaltrials.gov identifier NCT Phase 2 Randomized Multicenter Study of Extended Dosing Schedules of Oral Ezatiostat HCl (Telintra), a Glutathione Analog Prodrug GSTP1-1 Inhibitor, In Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS) (Abstract 2910a) Azra Raza, Naomi Galili, Scott Smith, John E. Godwin, Ralph Boccia, Han Myint, Daruka Mahadevan, Deborah Mulford, Mark Rarick, Mary Ann Allison, Ostap Melnyk, Lisa Meng, Marsha Jones, Gail Brown, Shelby A Young, and Mikkael A. Sekeres 10
11 Phase 2 Oral Ezatiostat Response Type 3000 mg/day 2 wks on/1 wk off (n=30) 2000 mg/day 3 wks on/1 wk off (n=31) Total (n=61) HI E (%) (95% CI) 7 (24) (10 44) 6 (19) (8 38) 13 (22) (12 34) HI N (%) (95% CI) 1 (10) (0 45) 3 (27) (6 61) 4 (19) (5 42) HI P (%) (95% CI) 1 (7) (0 34) 0 (0) (0 25) 1 (4) (0 19) Bilineage (HI-E and HI-N) (%) (95% CI) 1 (11) (0 48) 3 (27) (6 61) 4 (20) (6 44) Trilineage (HI-E, HI-N, and HI-P) (%) (95% CI) 1 (17) (0 64) 0 (0) (0 52) 1 (9) (0 41) Median Time (Weeks) to HI-E Response (Range) 8 (8 10) 8 (8 11) 8 (8 11) Median Duration (Weeks) of HI-E Response (Range) 18 (2 51) 46 (2 63) 34 (2 63) # of RBC Transfusion Dependent Patients (%) 20 (69) 18 (58) 38 (63) RBC Transfusions Reduced by 4U/8wks (%) (95% CI) 6 (30) (12 54) 5 (28) (10 54) 11 (29) (15 46) RBC Transfusion Independence (%) (95% CI) 1 (5) (0 25) 3 (17) (4 41) 4 (11) (3 25) Raza et al. Blood 2010;116:2910a Steensma HemOncClin NA 2010 IV Clofarabine MDS Study Eligible: MDS or CMML with either >5% blasts or IPSS Int-2/High risk Treatment: Clofarabine, either 15 or 30 mg/m2/day IV for 5 consecutive days, repeat every 4-6 wks Patients: 58 patients enrolled 40% >70 years old 74% with IPSS Int-2/High risk disease 60% had tried azacitidine or decitabine or both 26% had a prior malignancy 1 RA, 15 RAEB-1, 26 RAEB-2, 9 CMML,7 RAEB-t Jabbour E et al ASCO 2010; abstract
12 IV Clofarabine in MDS: Results Any response Overall (n=58) 15 mg/m2 dose (n=37) 30 mg/m2 dose (n=21) 21 (36%) 15 (41%) 6 (29%) CR (%) 15 (26%) 10 (27%) 5 (24%) HI (%) 6 (10%) 5 (14%) 1 (5%) Died by 8 weeks Alive at one year 11 (19%) 5 (14%) 6 (29%) 37% 37% 38% Jabbour E et al ASCO 2010; abstract 6504 IV Clofarabine in MDS: Adverse Effects Common: Nausea/vomiting Diarrhea Skin rash Liver test abnormalities Serious (grade 3 or 4): Infections (45%, more common with higher dose) Renal failure (6 patients, 4 with higher dose) Preliminary Results of Fixed-Dose Oral Clofarabine (CLO) In Patients Who Have Failed Hypomethylating Agents for the Treatment of Myelodysplastic Syndromes (MDS) (Abstract 1869) Mikkael A. Sekeres, Gail J. Roboz, Olatoyosi Odenike, Edward Agura, Bayard L. Powell, Reginald Ewesuedo, Michael J. Vasconcelles, Stefan Faderl, and Hagop Kantarjian 12
13 Oral Clo for Patients Failing Hypomethylating Agents Sekeres et al. Blood 2010;116:1869a. Oral Clo for Patients Failing Hypomethylating Agents Sekeres et al. Blood 2010;116:1869a. ON Na - Multikinase Inhibitor Cell-cycle functions and localizations of Plk1 ON Na Multikinase inhibitor Polo-like kinase 1 modulator? PI3K/Akt/ERK pathway inhibitor Induces Bim, inhibits Mcl-1 activation Reduces cyclin D1 levels Barr F et al Nature Reviews Molecular Cell Biology 2004; 5:
14 % aneuploidy % aneuploidy 3/21/2011 ON Na Development History = Ongoing MDS/AML study recruiting pts per clinicaltrials.gov Source: ON Na Suppresses Cyclin D1 Accumulation in trisomy 8 Myelodysplastic Syndromes Patients While Decreasing Bone Marrow CD34+ Blast Counts and Aneuploid Clone Size Ongoing studies NIH (9) and St Vincents (6) 15 pts with treatment-refractory IPSS Int-1 to High risk MDS or AML (2 AML; 7 with trisomy 8) (13 pts at St Vincents reported in another abstract) Escalating doses: 800 mg/m2/day over 48 hours continuous IV 3 weeks out of 4 up to 1500 mg/m2/day over 48 hours continuous IV 3 weeks out of 4 Most common AEs: cytopenias, nausea, fatigue Responses: StV: One patient RBC transfusion-independent x 14 mos, one patient with neutrophil response; 2/6 pts with increased blasts reduced (2 progressed, 2 stable) NIH: 1 HI-E, 2 HI-N, 2 bilineage responses Sloand E et al ASH 2009 Abstract #120 Raza A et al ASH 2009 Abstract # Aneuploidy During ON Na Treatment Baseline After 4-8 weeks of treatment Blast Proportion During ON Na Treatment Baseline After 4-8 weeks of treatment Sloand E et al ASH 2009 Abstract #120 Raza A et al ASH 2009 Abstract #
15 Predicted Probability of Response (PPR) to Immunosuppressive Therapy in MDS Age of the patient (years) + Duration of transfusion dependence (months) HLA DRB15 - HLA DRB15 + PPR >57 >71 Low (0-40%) High (41-100%) Validation Cohort (n=23) PPR Total Response No Response Low (0-40%) 14 1 (7%) 13 (93%) High (41-100%) 9 6 (67%) 3 (33%) Saunthararajah Y et al Blood (8): Phase II: Alemtuzumab in IPSS Int-1/Int-2 MDS With High PPR For Immunosuppressive Therapy Key Eligibility (goal n=39): De novo MDS with cytopenias and <5% blasts High likelihood (PPR) of IST response (using 2003 formula) No prior ATG/CSA Regimen: Alemtuzumab (anti-cd52) test dose, then 10 mg IV/day x 10 days TMP/SMX and valgancyclovir prophylaxis Results: Enrolled patients younger (median ~53 years old) and more hypocellular (45%) than a typical MDS population IWG responses in 15/16 (93%) with Int-1 MDS, 2/5 (40%) with Int-2 Cytogenetic remission in 5/7 Transient EBV positivity in 4/22 Sloand EM et al Abstract #116 - ASH
IPSS Modified 7/27/2011. WHO-Based Prognostic Scoring System (WPSS)
Advances in MDS Treatment: What s on the Horizon? New Prognostic Models and Therapies Jason Gotlib, MD, MS Assistant Professor of Medicine (Hematology) Stanford Cancer Center AA&MDSIF July 3, 011 WHO-Based
More informationLow Risk MDS Scoring System. Prognosis in Low Risk MDS. LR-PSS Validation 9/19/2012
Advances in MDS What s on the Horizon Tapan M. Kadia, MD Department of Leukemia MD Anderson Cancer Center Outline Newer Prognostic Systems Hypomethylating agent failures Newer Treatment approaches Role
More informationCREDIT DESIGNATION STATEMENT
CME Information LEARNING OBJECTIVES Recall the dose-limiting toxicity and preliminary clinical response results with 14- and 21-day extended treatment schedules of daily oral azacitidine. Apply new research
More informationAcute Myeloid Leukemia
Acute Myeloid Leukemia Pimjai Niparuck Division of Hematology, Department of Medicine Ramathibodi Hospital, Mahidol University Outline Molecular biology Chemotherapy and Hypomethylating agent Novel Therapy
More informationLa lenalidomide: meccanismo d azione e risultati terapeutici. F. Ferrara
La lenalidomide: meccanismo d azione e risultati terapeutici F. Ferrara MDS: new treatment goals Emerging treatment options expected to facilitate shift from supportive care to active therapy in MDS New
More informationEmerging Treatment Options for Myelodysplastic Syndromes
Emerging Treatment Options for Myelodysplastic Syndromes James K. Mangan, MD, PhD Assistant Professor of Clinical Medicine Abramson Cancer Center, University of Pennsylvania Please note that some of the
More informationA Phase II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndromes (MDS)
A Phase II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndromes (MDS) Shyamala C. Navada, MD 1, Lewis R. Silverman, MD 1, Katherine Hearn, RN 2, Rosalie
More information[ NASDAQ: MEIP ] Analyst & Investor Event December 8, 2014
[ NASDAQ: MEIP ] Analyst & Investor Event December 8, 2014 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements. Actual events or results may
More informationEmerging Treatment Options for Myelodysplastic Syndromes
Emerging Treatment Options for Myelodysplastic Syndromes James K. Mangan, MD, PhD Assistant Professor of Clinical Medicine Abramson Cancer Center, University of Pennsylvania Please note that some of the
More informationDisclosure Slide. Research Support: Onconova Therapeutics, Celgene
Oral Rigosertib Combined with Azacitidine in Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS): Effects in Treatment Naïve and Relapsed- Refractory Patients Shyamala C. Navada,
More informationDepartment of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, Texas; 2 Sunesis Pharmaceuticals, Inc, South San Francisco
Phase I/II Study of Vosaroxin and Decitabine in Newly Diagnosed Older Patients with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) Naval Daver 1, Hagop Kantarjian 1, Guillermo
More informationCombination of Oral Rigosertib and Injectable Azacitidine in Patients with Myelodysplastic Syndromes (MDS)
Combination of Oral Rigosertib and Injectable Azacitidine in Patients with Myelodysplastic Syndromes (MDS) Shyamala C. Navada, MD 1, Guillermo Garcia-Manero, MD 2, Katherine Hearn, RN 2, Rosalie Odchimar-Reissig,
More informationOn Behalf of the SGI-110 Investigative Team
First clinical results of a randomized phase 2 study of SGI-110, a novel subcutaneous hypomethylating agent, in 102 patients with Intermediate or High Risk MDS or CMML n Behalf of the SGI-110 Investigative
More informationDepartment of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, Texas; 2 Sunesis Pharmaceuticals, Inc, South San Francisco
Phase I/II Study of Vosaroxin and Decitabine in Newly Diagnosed Older Patients with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) Naval Daver 1, Hagop Kantarjian 1, Guillermo
More informationMaintaining Long-Term Efficacy in the Elderly MDS Patient with Poor Performance Status
Hi, my name is Dr. Hetty Carraway. I am a staff physician at the Taussig Cancer Institute at the Cleveland Clinic. Welcome to Managing MDS. 1 As you all are aware, many of our patients with MDS are in
More informationEnasidenib Monotherapy is Effective and Well-Tolerated in Patients with Previously Untreated Mutant-IDH2 Acute Myeloid Leukemia
Enasidenib Monotherapy is Effective and Well-Tolerated in Patients with Previously Untreated Mutant-IDH2 Acute Myeloid Leukemia Pollyea DA 1, Tallman MS 2,3, de Botton S 4,5, DiNardo CD 6, Kantarjian HM
More informationIDH1 AND IDH2 MUTATIONS
Mutant Isocitrate Dehydrogenase (midh) Inhibitors, Enasidenib or Ivosidenib, in Combination with Azacitidine (AZA): Preliminary Results of a Phase 1b/2 Study in Patients with Newly Diagnosed Acute Myeloid
More informationCombination Therapies in Higher-risk MDS
Combination Therapies in Higher-risk MDS Mikkael A. Sekeres, MD, MS Associate Professor of Medicine Director, Leukemia Program Taussig Cancer Institute U.S. Classification of MDS Patients 26% 18% 23% 15%
More informationAML in elderly. D.Selleslag AZ Sint-Jan Brugge, Belgium 14 December 2013
AML in elderly D.Selleslag AZ Sint-Jan Brugge, Belgium 14 December 2013 AML is predominantly a disease of the elderly incidence 2 3/100.000 SEER Cancer Statistics, National Cancer Institute, USA 2002 2006
More informationSummary of Key AML Abstracts Presented at the European Hematology Association (EHA) June 22-25, 2017 Madrid, Spain
Summary of Key AML Abstracts Presented at the European Hematology Association (EHA) June 22-25, 2017 Madrid, Spain EHA 2017 ANNUAL MEETING: ABSTRACT SEARCH PAGE: https://learningcenter.ehaweb.org/eha/#!*listing=3*browseby=2*sortby=1*media=3*ce_id=1181*label=15531
More informationMDS-004 Study: REVLIMID (lenalidomide) versus Placebo in Myelodysplastic Syndromes with Deletion (5q) Abnormality
MDS-4 Study: REVLIMID (lenalidomide) versus Placebo in Myelodysplastic Syndromes with Deletion (5q) Abnormality TABLE OF CONTENTS Section 1. Executive Summary Section 2. Background Section
More informationENASIDENIB IN MUTANT-IDH2 RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (R/R AML): RESULTS OF A PHASE 1 DOSE- ESCALATION AND EXPANSION STUDY
ENASIDENIB IN MUTANT-IDH2 RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (R/R AML): RESULTS OF A PHASE 1 DOSE- ESCALATION AND EXPANSION STUDY Eytan M. Stein, Courtney D. DiNardo, Daniel A. Pollyea, Amir
More informationEHA 2017 Abstracts: 4 Abstracts ( 1 Oral Presentation, 2 EPosters, 1 Publication)
EHA 2017 Abstracts: 4 Abstracts ( 1 Oral Presentation, 2 EPosters, 1 Publication) ORAL RIGOSERTIB COMBINED WITH AZACITIDINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) AND MYELODYSPLASTIC SYNDROMES (MDS):
More informationRaza et al. Journal of Hematology & Oncology 2012, 5:18
Raza et al. Journal of Hematology & Oncology 2012, 5:18 JOURNAL OF HEMATOLOGY & ONCOLOGY RESEARCH Open Access Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in
More informationLD-ARA-C and Clofarabine
LD-ARA-C and Clofarabine INDICATION Induction plus consolidation chemotherapy for patients with acute myeloid leukaemia (AML). Its use is particularly for patients over 60 years of age but it can be applied
More informationDr Kavita Raj Consultant Haematologist Guys and St Thomas Hospital
Dr Kavita Raj Consultant Haematologist Guys and St Thomas Hospital IPSS scoring system Blood counts Bone marrow blast percentage Cytogenetics Age as a modulator of median survival IPSS Group Median Survival
More informationShyamala Navada, MD Icahn School of Medicine at Mount Sinai. 60th ASH Annual Meeting & Exposition 2018: San Diego, CA, USA 1
Phase 2 Expansion Study of Oral Rigosertib Combined with Azacitidine (AZA) in Patients with Higher-Risk (HR) Myelodysplastic Syndromes: Efficacy and Safety Results in HMA Treatment Naive & Relapsed/Refractory
More informationCause of Death in Patients With Lower-Risk Myelodysplastic Syndrome
Original Article Cause of Death in Patients With Lower-Risk Myelodysplastic Syndrome Farshid Dayyani, MD, PhD 1 ; Anthony P. Conley, MD 1 ; Sara S. Strom, PhD 2 ; William Stevenson, MBBS, PhD 3 ; Jorge
More informationBackground CPX-351. Lancet J, et al. J Clin Oncol. 2017;35(suppl): Abstract 7035.
Overall Survival (OS) With Versus in Older Adults With Newly Diagnosed, Therapy-Related Acute Myeloid Leukemia (taml): Subgroup Analysis of a Phase 3 Study Abstract 7035 Lancet JE, Rizzieri D, Schiller
More informationMyelodysplastic Syndromes. Post-ASH meeting 2014 Marie-Christiane Vekemans
Myelodysplastic Syndromes Post-ASH meeting 2014 Marie-Christiane Vekemans Agenda New biological developments Risk assessment and prognostic factors New therapeutic options Agenda New biological developments
More informationSafety and Efficacy of Venetoclax Plus Low-Dose Cytarabine in Treatment-Naïve Patients Aged 65 Years With Acute Myeloid Leukemia
Safety and Efficacy of Venetoclax Plus Low-Dose Cytarabine in Treatment-Naïve Patients Aged 65 Years With Acute Myeloid Leukemia Abstract 102 Wei AH, Strickland SA, Roboz GJ, Hou J-Z, Fiedler W, Lin TL,
More informationThe Changing Face of MDS: Advances in Treatment
Thank you very much again for listening to me. We are going to be talking now in terms of therapy of MDS or The Changing Face of MDS Advances in Treatment. My name is Guillermo Garcia-Manero. I am a Professor
More informationMyelodysplastic Syndromes (MDS) Enhancing the Nurses Role in Management
Myelodysplastic Syndromes (MDS) Enhancing the Nurses Role in Management Christa Roe, RN, BS, OCN Malignant Hematology Department H Lee Moffitt Cancer Center & Research Tampa, Florida Agenda MDS Disease
More informationASCO 2011: Leukemia. Disclosures
ASCO 2011: Leukemia E.J. Feldman M.D Weill-Cornell Medical College Disclosures Speaker does not report any affiliations 1 V617F JAK2 mutation in MPDs JAK STAT PATHWAY Signal transducers and activators
More informationDisrupting the Cell Cycle to Treat AML and MDS Rodman & Renshaw Conference
CYC 682 Disrupting the Cell Cycle to Treat AML and MDS Rodman & Renshaw Conference September 2014 Disclaimer This presentation contains forward-looking statements within the meaning of the safe harbor
More informationMDS FDA-approved Drugs
MDS: Current Thinking on the Disease, Diagnosis, and Treatment Mikkael A. Sekeres, MD, MS Associate Professor of Medicine Director, Leukemia Program Dept of Hematologic Oncology and Blood Disorders Taussig
More informationThis is a controlled document and therefore must not be changed
AZACITIDINE NICE TA218 Treatment of adults not eligible for haematopoietic stem cell transplantation who have: Intermediate-2 and high-risk MDS according to the International Prognostic Scoring System
More informationBendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma
Bendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma Friedberg JW et al. Proc ASH 2009;Abstract 924. Introduction > Bendamustine (B)
More informationAre we always prolonging survival?
New therapies for myelodysplastic syndromes beyond hypomethylating agents and IMIDs Valeria Santini UF Ematologia, Università di Firenze Lisbon, May 4 th, 2012 Are we always prolonging survival? 1 Survival
More informationScottish Medicines Consortium
Scottish Medicines Consortium azacitidine 100mg powder for suspension for injection (Vidaza ) No. (589/09) Celgene Ltd 05 March 2010 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationAddition of Rituximab to Fludarabine and Cyclophosphamide in Patients with CLL: A Randomized, Open-Label, Phase III Trial
Addition of Rituximab to Fludarabine and Cyclophosphamide in Patients with CLL: A Randomized, Open-Label, Phase III Trial Hallek M et al. Lancet 2010;376:1164-74. Introduction > In patients with CLL, the
More informationNon-transplant Therapy for MDS. Bart Scott, MD Associate Member, FHCRC Associate Professor, UWMC
Non-transplant Therapy for MDS Bart Scott, MD Associate Member, FHCRC Associate Professor, UWMC MDS Treatment Algorithm Asymptomatic Symptomatic Bone Marrow Function Low/Int-1 Int-2/High Observation Cytokine
More informationA Phase 1 Trial of Lenalidomide (REVLIMID ) With Bortezomib (VELCADE ) in Relapsed and Refractory Multiple Myeloma
A Phase 1 Trial of Lenalidomide (REVLIMID ) With Bortezomib (VELCADE ) in Relapsed and Refractory Multiple Myeloma P.G. Richardson, 1 R. Schlossman, 1 N. Munshi, 1 D. Avigan, 2 S. Jagannath, 3 M. Alsina,
More informationNational Horizon Scanning Centre. Decitabine (Dacogen) for myelodysplastic syndrome. April 2008
Decitabine (Dacogen) for myelodysplastic syndrome April 2008 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be
More informationDecitabine Improves Patient Outcomes in Myelodysplastic Syndromes
1794 Decitabine Improves Patient Outcomes in Myelodysplastic Syndromes Results of a Phase III Randomized Study Hagop Kantarjian M.D. 1 Jean-Pierre J. Issa, M.D. 1 Craig S. Rosenfeld, M.D., Ph.D. 2 John
More informationDisclosure. Study was sponsored by Karyopharm Therapeutics No financial relationships to disclose Other disclosures:
Combination of Selinexor with High-Dose Cytarabine and Mitoxantrone for Remission Induction in Acute Myeloid Leukemia is Feasible and Tolerable A Phase I Study (NCT02573363) Amy Y. Wang, Howie Weiner,
More informationOutline. Case Study 5/17/2010. Treating Lower-Risk Myelodysplastic Syndrome (MDS) Tapan M. Kadia, MD Department of Leukemia MD Anderson Cancer Center
Treating Lower-Risk Myelodysplastic Syndrome (MDS) Tapan M. Kadia, MD Department of Leukemia MD Anderson Cancer Center Outline Case Study What is lower-risk MDS? Classification systems Prognosis Treatment
More informationTreating Higher-Risk MDS. Case presentation. Defining higher risk MDS. IPSS WHO IPSS: WPSS MD Anderson PSS
Treating Higher-Risk MDS Eyal Attar, M.D. Massachusetts General Hospital Cancer Center eattar@partners.org 617-724-1124 Case presentation 72 year old man, prior acoustic neuroma WBC (X10 3 /ul) 11/08 12/08
More informationNational Horizon Scanning Centre. Azacitidine (Vidaza) for myelodysplastic syndrome. September 2007
Azacitidine (Vidaza) for myelodysplastic syndrome September 2007 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationMDS: Who gets it and how is it diagnosed?
MDS: Who gets it and how is it diagnosed? October 16, 2010 Gail J. Roboz, M.D. Director, Leukemia Program Associate Professor of Medicine Weill Medical College of Cornell University The New York Presbyterian
More informationCLINICAL STUDY REPORT SYNOPSIS
CLINICAL STUDY REPORT SYNOPSIS Document No.: EDMS-PSDB-5412862:2.0 Research & Development, L.L.C. Protocol No.: R115777-AML-301 Title of Study: A Randomized Study of Tipifarnib Versus Best Supportive Care
More informationPhase 1 Study of ARRY-520 and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
Phase 1 Study of ARRY-520 and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Jatin J Shah, MD, Sheeba Thomas, MD, Donna Weber, MD, Michael Wang, MD, Raymond Alexanian, MD, Robert
More informationNew and Emerging Strategies in the Treatment of Patients with Higher risk Myelodysplastic Syndromes (MDS)
Welcome to Managing Myelodysplastic Syndromes. My name is David Steensma. I am an Associate Professor of Medicine at Harvard Medical School and a faculty member in the Adult Leukemia Program at Dana Farber
More informationSelinexor is an oral, slowly-reversible, first-inclass Selective Inhibitor of Nuclear Export (SINE)
Selinexor, a First-in-Class XPO1 Inhibitor, Is Efficacious and Tolerable in Patients with Myelodysplastic Syndromes (MDS) Refractory to Hypomethylating Agents Justin Taylor, MD, Morgan Coleman, MPH, Kelsey
More informationMyelodysplastic Syndromes without Deletion 5q Cytogenetic Abnormality and REVLIMID (lenalidomide)
Myelodysplastic Syndromes without Deletion 5q Cytogenetic Abnormality and REVLIMID (lenalidomide) INTRODUCTION Myelodysplastic syndromes (MDS) are a group of heterogeneous hematologic disorders
More informationASCO 2009 Leukemia MDS -Transplant
ASCO 2009 Leukemia MDS -Transplant Ruben A. Mesa, MD Professor of Medicine Mayo Clinic College of Medicine Scottsdale, AZ, USA mesa.ruben@mayo.edu American Society of Hematology State-of-the-Art Symposium
More informationOn behalf of Study SGI Investigators Team
Long Term Survival and Clinical Complete Responses of Various Prognostic Subgroups in 103 Relapsed/Refractory Acute Myeloid Leukemia (r/r AML) Patients Treated with Guadecitabine (SGI-110) in Phase 2 Studies
More informationLet s Look at Our Blood
Let s Look at Our Blood Casey O Connell, MD Associate Professor of Clinical Medicine Jane Anne Nohl Division of Hematology Keck School of Medicine of USC 10,000,000,000 WBCs/day Bone Marrow: The Blood
More informationPresented at the 58 th American Society of Hematology Annual Meeting and Exposition, December 5, 2016, San Diego, CA
1070 Determination of IDH1 mutational burden and clearance via next-generation sequencing in patients with IDH1 mutation-positive hematologic malignancies receiving AG-120, a first-in-class inhibitor of
More informationDana-Farber Cancer Institute, Boston, MA; 2 City of Hope National Medical Center, Duarte, CA; 3 Roswell Park Cancer Institute, Buffalo, NY; 4
Results from Ongoing Phase 2 Trial of SL-401 As Consolidation Therapy in Patients with Acute Myeloid Leukemia (AML) in Remission with High Relapse Risk Including Minimal Residual Disease (MRD) Andrew A.
More informationEmerging Treatment Options for Myelodysplastic Syndromes
Emerging Treatment Options for Myelodysplastic Syndromes James K. Mangan, MD, PhD Assistant Professor of Clinical Medicine Abramson Cancer Center, University of Pennsylvania Please note that some of the
More informationOverview. Myelodysplastic Syndromes: What s on the Horizon? Molecular Mutations in MDS. Refining Risk Models. Incorporating Mutational Data
Myelodysplastic Syndromes: What s on the Horizon? Vu H. Duong, MD, MS Assistant Professor of Medicine University of Maryland July 16, 2016 Overview Refining Risk models Specific Therapeutic Areas of Need
More informationNCCP Chemotherapy Regimen
INDICATIONS FOR USE: Azacitidine i INDICATION ICD10 Regimen Code *Reimbursement Status Intermediate-1 and low risk myelodysplastic syndromes (MDS) according to the International Prognostic Scoring System
More informationDana-Farber Cancer Institute, Boston, MA, USA; 2. H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA; 3
The investigational agent MLN9708, an oral proteasome inhibitor, in patients with relapsed and/or refractory multiple myeloma (MM): results from the expansion cohorts of a phase 1 dose-escalation study
More informationTreatment of Low-Blast Count AML. Maria Teresa Voso Dipartimento di Biomedicina e Prevenzione Università di Roma Tor Vergata
Treatment of Low-Blast Count AML Maria Teresa Voso Dipartimento di Biomedicina e Prevenzione Università di Roma Tor Vergata Definition of Low-Blast Count AML Blast counts 20-30%, or > 10%? v Retrospective
More informationUpdate on Chemotherapy- Induced Anemia and Neutropenia Therapies
Update on Chemotherapy- Induced Anemia and Neutropenia Therapies ASCO 2007: Update on Chemotherapy- Induced Anemia and Neutropenia Therapies Safety and efficacy of intravenous iron in patients with chemotherapyinduced
More informationIdelalisib in the Treatment of Chronic Lymphocytic Leukemia
Idelalisib in the Treatment of Chronic Lymphocytic Leukemia Jacqueline C. Barrientos, MD Assistant Professor of Medicine Hofstra North Shore LIJ School of Medicine North Shore LIJ Cancer Institute CLL
More informationOncology Highlights: Leukemia & Myelodysplastic Syndromes
Oncology Highlights: Leukemia & Myelodysplastic Syndromes Jorge Cortes, MD Department of Leukemia The University of Texas, M.D. Anderson Cancer Center Highlights of the Day Leukemia & MDS AML: The field
More informationMDS 101. What is bone marrow? Myelodysplastic Syndrome: Let s build a definition. Dysplastic? Syndrome? 5/22/2014. What does bone marrow do?
101 May 17, 2014 Myelodysplastic Syndrome: Let s build a definition Myelo bone marrow Gail J. Roboz, M.D. Director, Leukemia Program Associate Professor of Medicine What is bone marrow? What does bone
More informationMyelodysplastic syndrome. Jeanne Palmer, MD Mayo Clinic, Arizona
Myelodysplastic syndrome Jeanne Palmer, MD Mayo Clinic, Arizona What is Myelodysplastic syndrome? A disease where the bone marrow doesn t work appropriately What does that mean?? Red blood cells Carry
More informationNew Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders
New Evidence reports on presentations given at EHA/ICML 2011 Bendamustine in the Treatment of Lymphoproliferative Disorders Report on EHA/ICML 2011 presentations Efficacy and safety of bendamustine plus
More informationUse of TPO mimetics for Indications Other Than ITP
Use of TPO mimetics for Indications Other Than ITP Mazyar Shadman, MD, MPH Discussant: Siobán Keel, MD Hematology Fellows Conference June 28, 2013 Thrombopoietin (TPO) and other c mpl ligands TPO mimetics
More informationRandomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN
Regular Article CLINICAL TRIALS AND OBSERVATIONS Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN Elias Jabbour, 1 Nicholas J. Short, 1 Guillermo Montalban-Bravo,
More informationMyelodysplastic Syndrome: Let s build a definition
1 MDS: Diagnosis and Treatment Update Gail J. Roboz, M.D. Director, Leukemia Program Associate Professor of Medicine Weill Medical College of Cornell University The New York Presbyterian Hospital Myelodysplastic
More informationNew concepts in the management of elderly patients with AML
New concepts in the management of elderly patients with AML Martha L. Arellano, MD Associate Professor of Hematology/Oncology Director, Hematology & Medical Oncology Fellowship Program Winship Cancer Institute
More informationEnhancing Survival Outcomes in the Management of Patients With Higher-Risk Myelodysplastic Syndromes
The classification, diagnosis, treatment goals, clinical experience, guidelines, and therapeutic options for higher-risk MDS patients are reviewed. Anne Silber. Ha Long Bay, Vietnam (detail). Limited edition
More informationManagement of low and high risk MDS
Management of low and high risk MDS D.Selleslag AZ Sint-Jan Brugge, Belgium Brussels, 4th October 2014 Low / int 1 risk MDS Improve QOL Improve cytopenia Int 2 / high risk MDS Delay progression To AML
More informationVYXEOS : CHEMOTHERAPY LIPOSOME INJECTION FOR ACUTE MYELOID LEUKEMIA
VYXEOS : CHEMOTHERAPY LIPOSOME INJECTION FOR ACUTE MYELOID LEUKEMIA Sarah Mae Rogado PharmD Candidate 2017 Preceptors: Rozena Varghese, PharmD, CMPP; Rachel Brown, PharmD MedVal Scientific Information
More informationSmoldering Myeloma: Leave them alone!
Smoldering Myeloma: Leave them alone! David H. Vesole, MD, PhD Co-Director, Myeloma Division Director, Myeloma Research John Theurer Cancer Center Hackensack University Medical Center Prevalence 1960 2002
More informationOral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study
Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study Hagop Kantarjian, University of Texas MD Anderson Cancer Center Stefan Faderl, University
More informationClinical Roundtable Monograph
Clinical Roundtable Monograph C l i n i c a l A d v a n c e s i n H e m a t o l o g y & O n c o l o g y A u g u s t 2 0 0 9 Evolving Strategies in the Treatment of MDS and AML Faculty Richard Stone, MD
More informationCurrent guidelines for management of INT- 2/high risk MDS
ELASTIC Current guidelines for management of INT- 2/high risk MDS If fit (i.e. HCT-CI and performance status< 3), consider for early allo BMT with/without prior AML induction therapy If unfit consider
More informationTREATMENT UPDATES IN ACUTE LEUKEMIA. Shannon McCurdy, MD University of Pennsylvania
TREATMENT UPDATES IN ACUTE LEUKEMIA Shannon McCurdy, MD University of Pennsylvania TIMELINE FOR FDA APPROVED AGENTS FOR AML Midostuarin Enasidenib Cytarabine + Daunorubicin (7+3) Gemtuzumab Ozogamicin
More informationWelcome and Introductions
MDS: Update on Treatment and Side Effects Management Azra Raza, MD Professor of Medicine Director, MDS Center Columbia University Medical Center Milstein Hospital Building New York, NY Antonietta de los
More informationDarbepoetin alfa (Aranesp) for treatment of anaemia in adults with low or intermediate-1-risk myelodysplastic syndromes
NIHR Innovation Observatory Evidence Briefing: August 2017 Darbepoetin alfa (Aranesp) for treatment of anaemia in adults with low or intermediate-1-risk myelodysplastic syndromes NIHRIO (HSRIC) ID: 13763
More informationMDS overview 전남대학교김여경
MDS overview 전남대학교김여경 2008 WHO Classification of MDS Name Abbreviation Key Feature Pts, % Refractory cytopenia, with unlineage, dysplasia Refractory anemia with ring sideroblasts RA Anemia and erythroid
More informationIvosidenib (IVO; AG-120) in mutant IDH1 relapsed/refractory acute myeloid leukemia (R/R AML): Results of a phase 1 study
7000 Ivosidenib (IVO; AG-120) in mutant IDH1 relapsed/refractory acute myeloid leukemia (R/R AML): Results of a phase 1 study Daniel A Pollyea 1, Courtney D DiNardo 2, Stéphane de Botton 3, Eytan M Stein
More informationH. Lee Moffitt Cancer Center and Research Institute, University of California, San Francisco & Tisch Cancer Institute, Mount Sinai School of Medicine
Pomalidomide, Cyclophosphamide, and Dexamethasone Is Superior to Pomalidomide and Dexamethasone in Relapsed and Refractory Myeloma: Results of a Multicenter Randomized Phase II Study Rachid Baz, Thomas
More informationA Phase I Dose-Escalation Study of Clofarabine in Patients with Relapsed or Refractory Low-Grade or Intermediate-Grade B-Cell or T-Cell Lymphoma
Clinical Trial Results A Phase I Dose-Escalation Study of Clofarabine in Patients with Relapsed or Refractory Low-Grade or Intermediate-Grade B-Cell or T-Cell Lymphoma FRANCINE MARIE FOSS, TERRI PARKER
More informationCorrespondence should be addressed to Anas Khanfar;
Case Reports in Oncological Medicine, Article ID 949515, 4 pages http://dx.doi.org/10.1155/2014/949515 Case Report Durable Hematological and Major Cytogenetic Response in a Patient with Isolated 20q Deletion
More informationThis was a multicenter study conducted at 11 sites in the United States and 11 sites in Europe.
Protocol CAM211: A Phase II Study of Campath-1H (CAMPATH ) in Patients with B- Cell Chronic Lymphocytic Leukemia who have Received an Alkylating Agent and Failed Fludarabine Therapy These results are supplied
More informationMyelodysplastic Syndromes: Challenges to Improving Patient and Caregiver Satisfaction
Supplement issue Myelodysplastic Syndromes: Challenges to Improving B. Douglas Smith, MD Division of Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins
More informationManufacturer: Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.
Brand Name: Mylotarg Generic Name: gentuzumab ozogamicin Manufacturer: Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc. Drug Class: CD33-directed antibody-drug conjugate Uses: Labeled Uses: Newly-diagnosed
More informationHow to Integrate the New Drugs into the Management of Multiple Myeloma
How to Integrate the New Drugs into the Management of Multiple Myeloma Carol Ann Huff, MD The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins NCCN.org For Clinicians NCCN.org/patients For Patients
More informationSupplementary Materials for
Supplementary Materials for A Clinical Trial for Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes Not Eligible for Standard Clinical Trials Table of Contents Content Page Supplementary
More informationCombinational therapy and newer agents in MDS- Prof Ghulam.J.Mufti MDS foundation ASH 2011
Combinational therapy and newer agents in MDS- Prof Ghulam.J.Mufti MDS foundation ASH 2011 My Disclosures Advisory board member of GSK, Novartis, Roche and Celgene Unrestricted educational grants from
More informationTreatment of low risk MDS
Treatment of low risk MDS Matteo G Della Porta Cancer Center IRCCS Humanitas Research Hospital & Humanitas University Rozzano Milano, Italy matteo.della_porta@hunimed.eu International Prognostic Scoring
More informationThe immunomodulatory agents lenalidomide and thalidomide for treatment of the myelodysplastic syndromes: A clinical practice guideline
Critical Reviews in Oncology/Hematology 85 (2013) 162 192 The immunomodulatory agents lenalidomide and thalidomide for treatment of the myelodysplastic syndromes: A clinical practice guideline Heather
More informationDisclosures. Membership of Advisory Committees: Research Support/ PI: Celgene Corporation Millennium Pharmaceuticals Johnson & Johnson
Randomized, Open-Label Phase 1/2 Study of Pomalidomide Alone or in Combination With Low-Dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That
More informationAML IN OLDER PATIENTS Whenever possible, intensive induction therapy should be considered
AML IN OLDER PATIENTS Whenever possible, intensive induction therapy should be considered Charles A. Schiffer, M.D. Karmanos Cancer Institute Wayne State University School of Medicine Detroit, MI WHY ARE
More information